Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred stock financing. Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants. New investors, including D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, joined the company's existing investors to complete the round.

"Raising funds from this outstanding group of investors in this challenging market validates the potential value of our novel product candidates for thrombosis, one of the world's largest markets," said Charles Homcy, M.D., president and chief executive officer of Portola. "These funds will also help us advance a novel Factor Xa inhibitor antidote and our Syk and JAK inhibitor program, which further diversify the company's pipeline and may offer opportunities for accelerated product development."

Two Clinical Candidates Address Global Thrombosis Market

Portola is advancing two differentiated drug candidates that address the global, multi-billion dollar antithrombotic market where existing drugs, such as enoxaparin (Lovenox(R)), clopidogrel (Plavix(R)) and warfarin (Coumadin(R)), have well known limitations.

Betrixaban, the company's first Phase 2 drug candidate, is an oral Factor Xa inhibitor. Factor Xa is a validated target for which there are approved drugs on the market, and inhibiting its activity is bel
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Research and Markets  has announced ... Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal ... http://photos.prnewswire.com/prnh/20130307/600769 ... in IVD testing with competitive participation by top ... criminal justice personnel, and sports use drug tests ...
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2
... Mass. , Feb. 4 Recognizing that corporate ... they contain, Northern Light ( www.northernlight.com ) today announced that ... excess of $2 billion can be searched, analyzed ... been steadily increasing the number of market research sources integrated ...
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
Cached Medicine Technology:Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 2Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 3Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2
(Date:8/1/2014)... August 01, 2014 As AndroGel lawsuits ... country, Ronald E. Johnson, Jr. has been appointed as ... and other testosterone medications. Since the Fall of 2013, ... have worked diligently to investigate and prosecute the claims ... and blood clots as a result of taking testosterone. ...
(Date:8/1/2014)... a cancer diagnosis may improve health outcomes for Asian-American ... a researcher at the University of Houston (UH). ... is the writing instruction. Otherwise, writing is just like ... can be therapeutic, but oftentimes we don,t get the ... said Qian Lu, assistant professor and director of the ...
(Date:8/1/2014)... August 01, 2014 Growing prevalence ... and healthcare reforms are boosting healthcare market growth, ... through discounts and increasing generic consumption is a ... 76.7 million in 2013, having grown at a ... 2008. The implementation of the Health Transformation Program ...
(Date:8/1/2014)... Hot off the presses after the announcement of ... World’s Best Awards by Travel + Leisure , The ... Relaxation Day (technically August 15). , The Lodge at ... help guests celebrate relaxation throughout the month of August. ... wellness to carve out time to relax and unwind. ...
(Date:8/1/2014)... 2014 The "Antimicrobial Coatings Market ... Zinc Oxide, Titanium Dioxide, and Zinc Omadine), Application ... Food & Beverages, Textiles, and others), & Geography ... Trends and Forecasts to 2018" analyzes the Antimicrobial ... and trends in the diverse geographical regions. , ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4
... General Hospital,became the first hospital in Palm Beach County ... Electronic Birth Registry (EBR) system,launched on August 8, Glades ... reducing the costs and processing time. Now,the staff at ... the,report, and get the required electronic signatures -- all ...
... ATSI ), manufacturer and marketer of state-of-the-art ... will present at the,2007 Thomas Weisel Partners Healthcare ... Company,s presentation is scheduled for Wednesday, September,5, 2007 ... and CEO of ATS,Medical, will present a review ...
... Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an over-the-counter healthcare ... "Better Ways to Get,Better(R)," will be presenting on September ... Conference. The Company will be presenting at 11:30 ... http://www.matrixxinc.com . Interested parties,should login 15 minutes prior ...
... in,health-related research grew by a modest 4.2% from 2005 ... health costs, according,to a report released today by Research!America. ... Science. The nation spent approximately $116 billion last ... and prevent disease and disability. This,represents a decrease relative ...
... in Italian study , , THURSDAY, Aug. 30 (HealthDay News) -- ... of dying in the next year compared to those who ... number of other studies have shown the benefits of using ... instance, the Italian study comes on the heels of a ...
... A drug that shuts down a critical cell-signaling pathway ... brain cancer successfully kills cancer stem cells thought to ... radiation therapy, a Johns Hopkins study shows. , In ... scientists blocked the signaling system, known as Hedgehog, with ...
Cached Medicine News:Health News:Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration 2Health News:Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration 3Health News:ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2Health News:Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Health News:U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science 2Health News:Stopping Statins After Stroke Doubles Death Risk 2Health News:Stopping Statins After Stroke Doubles Death Risk 3Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
ELISA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
Medicine Products: